Inactive Instrument

Aceragen, Inc. Nyse

ACGN

US00445F1093

Biotechnology & Medical Research

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Growth Index

June 25, 2021 at 12:00 am EDT

Latest news about Aceragen, Inc.

Aceragen Inc is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Companyâs pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-2.30%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.25%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.88%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.91%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.97%	11.68B
MEDPACE HOLDINGS, INC.	+20.80%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.76%	11.15B

Other Biotechnology & Medical Research

Aceragen, Inc. Nyse

Equities

ACGN

US00445F1093

Biotechnology & Medical Research

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Growth Index

Latest news about Aceragen, Inc.

Chart Aceragen, Inc.

Company Profile

Sector Other Biotechnology & Medical Research